Cargando…
Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
BACKGROUND: Endometrial cancer (EC) is a hormone dependent carcinoma that may involve complex molecular mechanisms. Endocrine therapy by blocking the estrogen and estrogen receptor α (ERα) has been effective in breast cancer, while it is still controversial in EC. Recently, estrogen-related receptor...
Autores principales: | Mao, XiaoDan, Dong, Binhua, Gao, Min, Ruan, GuanYu, Huang, MeiMei, Braicu, Elena Ioana, Sehouli, Jalid, Sun, PengMing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709363/ https://www.ncbi.nlm.nih.gov/pubmed/31686835 http://dx.doi.org/10.2147/OTT.S216146 |
Ejemplares similares
-
Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA
por: Sun, PengMing, et al.
Publicado: (2018) -
Key regulator of cellular metabolism, estrogen-related receptor α, a new therapeutic target in endocrine-related gynecological tumor
por: Liu, GuiFen, et al.
Publicado: (2018) -
Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells
por: Sun, Pengming, et al.
Publicado: (2018) -
Lipid reprogramming induced by the TFEB-ERRα axis enhanced membrane fluidity to promote EC progression
por: Mao, Xiaodan, et al.
Publicado: (2022) -
ERRα inhibitor acts as a potential agonist of PPARγ to induce cell apoptosis and inhibit cell proliferation in endometrial cancer
por: Huang, Meimei, et al.
Publicado: (2020)